Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male/female 18-65 years old~2. Able to read, comprehend \& sign the informed consent form~3. Meet opioid dependence criteria in DSM-IV-TR the past 12 months~4. Have a buprenorphine-negative UDS \&/or urine dipstick~5. Prepared to abstain from opioids other than the study drug \& from other addictive drugs~6. Negative urine pregnancy test~7. Females of childbearing potential who use a reliable method of contraception. Females of non-childbearing potential; surgically sterile or post-menopausal as defined by being at least 50 years of age \& having an absence of menses for at least 2 years~8. Clearance from the prescribing MD to be withdrawn from their prescribed opioids for subjects receiving opioids for pain~9. Lack of clinically significant abnormalities in health assessments performed at screening. Unclear cases should be approved by the medical monitor~10. At least mild withdrawal symptoms (COWS ≥9)~Exclusion Criteria:~1. Pregnant, lactating or planning to be pregnant during study~2. Unwilling/unable to comply with the requirements of the protocol (e.g., pending incarceration) are in a situation/condition that may interfere with participation in the study~3. Prescribed treatment with generic buprenorphine monotherapy within 90 days prior start of treatment~4. Daily dose of methadone over 30 mg during the past week or who received the last dose of methadone less than 30 hours prior to treatment~5. Participating in other clinical studies in which medications is delivered or who have used an investigational drug/device within the last 30 days~6. Allergy, sensitivity or intolerance to BUP, NAL or any related drug; history of drug hypersensitivity or intolerance which, in the opinion of the investigator, would compromise the safety of the subject/study~7. Staff, affiliated with, or family member of the staff directly involved with this study~8. Serious untreated Axis I DSM-IV-TR psychiatric comorbidity (actively suicidal or homicidal, have untreated schizophrenia)~9. Tongue/oral deformities that may affect the absorption of the drug products~10. Current/history of clinically significant medical disorder or condition which would jeopardize the safety or impact the validity of the results. Unclear cases should be discussed with \& approved by the medical monitor~11. HIV-seropositive with a CD4+ count \<200, active AIDS defining infection in the last 120 days~12. Have Class III/IV congestive heart failure, symptomatic myocardial ischemia or history of long QT syndrome (or an immediate family member with this condition)~13. Currently taking Class 1A antiarrhythmic medications (e.g., quinidine, procainamide, \& disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, \& dofetilide)~14. Have uncontrolled hypertension, pulse oximetry ≤92%or clinically significant abnormality on 12-lead ECG, including a corrected QT (QTc) interval \>450 ms~15. Severe liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine; then OL BNX film, then BNX tablets (Type: ACTIVE_COMPARATOR): Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
- BNX tablets, then OL BNX tablets, then BNX film (Type: EXPERIMENTAL): Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).